Literature DB >> 18803353

Liver insulin-like growth factor 2 methylation in hepatitis C virus cirrhosis and further occurrence of hepatocellular carcinoma.

Philippe Couvert1, Alain Carrié, Jacques Pariès, Jenny Vaysse, Audrey Miroglio, Antoine Kerjean, Pierre Nahon, Jamel Chelly, Jean-Claude Trinchet, Michel Beaugrand, Nathalie Ganne-Carrié.   

Abstract

AIM: To assess the predictive value of the insulin-like growth factor 2 (Igf2) methylation profile for the occurrence of Hepatocellular Carcinoma (HCC) in hepatitis C (HCV) cirrhosis.
METHODS: Patients with: (1) biopsy-proven compensated HCV cirrhosis; (2) available baseline frozen liver sample; (3) absence of detectable HCC; (4) regular screening for HCC; (5) informed consent for genetic analysis were studied. After DNA extraction from liver samples and bisulfite treatment, unbiased PCR and DHPLC analysis were performed for methylation analysis at the Igf2 locus. The predictive value of the Igf2 methylation profile for HCC was assessed by Kaplan-Meier and Cox methods.
RESULTS: Among 94 included patients, 20 developed an HCC during follow-up (6.9 +/- 3.2 years). The methylation profile was hypomethylated, intermediate and hypermethylated in 13, 64 and 17 cases, respectively. In univariate analysis, two baseline parameters were associated with the occurrence of HCC: age (P = 0.01) and prothrombin (P = 0.04). The test of linear tendency between the three ordered levels of Igf2 methylation and probability of HCC occurrence was significant (Log Rank, P = 0.043; Breslow, P = 0.037; Tarone-Ware, P = 0.039).
CONCLUSION: These results suggest that hypomethylation at the Igf2 locus in the liver could be predictive for HCC occurrence in HCV cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18803353      PMCID: PMC2744164          DOI: 10.3748/wjg.14.5419

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  54 in total

Review 1.  Genomic imprinting: parental influence on the genome.

Authors:  W Reik; J Walter
Journal:  Nat Rev Genet       Date:  2001-01       Impact factor: 53.242

2.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

Authors:  J Bruix; M Sherman; J M Llovet; M Beaugrand; R Lencioni; A K Burroughs; E Christensen; L Pagliaro; M Colombo; J Rodés
Journal:  J Hepatol       Date:  2001-09       Impact factor: 25.083

3.  Long-term interferon therapy for 1 year or longer reduces the hepatocellular carcinogenesis rate in patients with liver cirrhosis caused by hepatitis C virus: a pilot study.

Authors:  K Ikeda; S Saitoh; M Kobayashi; Y Suzuki; F Suzuki; A Tsubota; Y Arase; N Murashima; K Chayama; H Kumada
Journal:  J Gastroenterol Hepatol       Date:  2001-04       Impact factor: 4.029

4.  Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis.

Authors:  A Gramenzi; P Andreone; S Fiorino; C Cammà; M Giunta; D Magalotti; C Cursaro; C Calabrese; V Arienti; C Rossi; G Di Febo; M Zoli; A Craxì; G Gasbarrini; M Bernardi
Journal:  Gut       Date:  2001-06       Impact factor: 23.059

5.  Molecular pathogenesis of human hepatocellular carcinoma.

Authors:  Snorri S Thorgeirsson; Joe W Grisham
Journal:  Nat Genet       Date:  2002-08       Impact factor: 38.330

6.  Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis.

Authors:  L Bolondi; S Sofia; S Siringo; S Gaiani; A Casali; G Zironi; F Piscaglia; L Gramantieri; M Zanetti; M Sherman
Journal:  Gut       Date:  2001-02       Impact factor: 23.059

7.  Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2.

Authors:  Hengmi Cui; Patrick Onyango; Sheri Brandenburg; Yiqian Wu; Chih-Lin Hsieh; Andrew P Feinberg
Journal:  Cancer Res       Date:  2002-11-15       Impact factor: 12.701

8.  Risk factors for the rising rates of primary liver cancer in the United States.

Authors:  H B El-Serag; A C Mason
Journal:  Arch Intern Med       Date:  2000-11-27

Review 9.  Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications.

Authors:  V Santini; H M Kantarjian; J P Issa
Journal:  Ann Intern Med       Date:  2001-04-03       Impact factor: 25.391

10.  A methylated oligonucleotide inhibits IGF2 expression and enhances survival in a model of hepatocellular carcinoma.

Authors:  Xiaoming Yao; Ji-Fan Hu; Mark Daniels; Hadas Shiran; Xiangjun Zhou; Huifan Yan; Hongqi Lu; Zhilan Zeng; Qingxue Wang; Tao Li; Andrew R Hoffman
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

View more
  10 in total

Review 1.  Targeting the insulin-like growth factor pathway in hepatocellular carcinoma.

Authors:  Mónica Enguita-Germán; Puri Fortes
Journal:  World J Hepatol       Date:  2014-10-27

Review 2.  Lin28 and let-7: roles and regulation in liver diseases.

Authors:  Kelly McDaniel; Chad Hall; Keisaku Sato; Terry Lairmore; Marco Marzioni; Shannon Glaser; Fanyin Meng; Gianfranco Alpini
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-03-24       Impact factor: 4.052

3.  Interplay between microRNA-17-5p, insulin-like growth factor-II through binding protein-3 in hepatocellular carcinoma.

Authors:  Danira Ashraf Habashy; Hend Mohamed El Tayebi; Injie Omar Fawzy; Karim Adel Hosny; Gamal Esmat; Ahmed Ihab Abdelaziz
Journal:  World J Hepatol       Date:  2016-08-18

4.  A pre-neoplastic epigenetic field defect in HCV-infected liver at transcription factor binding sites and polycomb targets.

Authors:  N A Wijetunga; M Pascual; J Tozour; F Delahaye; M Alani; M Adeyeye; A W Wolkoff; A Verma; J M Greally
Journal:  Oncogene       Date:  2016-10-10       Impact factor: 9.867

Review 5.  Insulin-Like Growth Factor (IGF) System in Liver Diseases.

Authors:  Agnieszka Adamek; Aldona Kasprzak
Journal:  Int J Mol Sci       Date:  2018-04-27       Impact factor: 5.923

Review 6.  The Good, the Bad, the Question-H19 in Hepatocellular Carcinoma.

Authors:  Lysann Tietze; Sonja M Kessler
Journal:  Cancers (Basel)       Date:  2020-05-16       Impact factor: 6.639

Review 7.  Molecular pathogenesis: Connections between viral hepatitis-induced and non-alcoholic steatohepatitis-induced hepatocellular carcinoma.

Authors:  Zelin Tian; Chen Xu; Peijun Yang; Zhibin Lin; Wenlong Wu; Wenjie Zhang; Jian Ding; Rui Ding; Xuan Zhang; Kefeng Dou
Journal:  Front Immunol       Date:  2022-09-15       Impact factor: 8.786

8.  Transient Hepatic Overexpression of Insulin-Like Growth Factor 2 Induces Free Cholesterol and Lipid Droplet Formation.

Authors:  Sonja M Kessler; Stephan Laggai; Elien Van Wonterg; Katja Gemperlein; Rolf Müller; Johannes Haybaeck; Roosmarijn E Vandenbroucke; Manfred Ogris; Claude Libert; Alexandra K Kiemer
Journal:  Front Physiol       Date:  2016-04-25       Impact factor: 4.566

9.  Loss of SRSF2 triggers hepatic progenitor cell activation and tumor development in mice.

Authors:  Chang Zhang; Lei Shen; Wei Yuan; Yuguo Liu; Ruochen Guo; Yangjun Luo; Zheng Zhan; Zhiqin Xie; Guohao Wu; Wenwu Wu; Ying Feng
Journal:  Commun Biol       Date:  2020-05-05

Review 10.  Molecular Mechanisms of Hepatocarcinogenesis Following Sustained Virological Response in Patients with Chronic Hepatitis C Virus Infection.

Authors:  C Nelson Hayes; Peiyi Zhang; Yizhou Zhang; Kazuaki Chayama
Journal:  Viruses       Date:  2018-09-28       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.